FDA grants list of orphans for pancreatic cancer at listal Genomics CG-745
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The U.SFood andMedicines(http://Administration (http://
http://has granted CG-745 orphan drug treatment for pancreatic cancer to the cg-745, the(http://announced.
CG-745 is a clinically active histone deacetylase (HDAC) inhibitor that is currently being developed for several hematologic malignancies and solid tumorsCrystal Genomics is currently conducting a Phase II clinical study to assess the safety and efficacy of CG-745 combined gixithabinandand and erotinib for the treatment of late localnonional or metastatic pancreatic cancerIn addition, there is another ongoing Phase II ClinicalTrial(http:// that is evaluating the safety and efficacy of patients with bone marrow hyperplasia syndrome (MDS) treated with CG-745 without low methylation therapy About Crystal Genomics
Crystal Genomics is a commercial-stage bio
Pharmaceutical (http:// company in Korea focused on structurally based drug discovery, development and commercialization of innovative therapies in areas of unmet needs of medical (http:// such as inflammation, oncology and infectious diseases
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
